From DDW:
Vedolizumab, ustekinumab best anti-TNF for infection risk in older adult IBD
SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations compared with anti-tumor necrosis factor agents in patients who initiated inflammatory bowel disease therapy at an older age. “It used to be thought that IBD becomes a milder disease with...
www.healio.com